Built around one powerful idea.
Calixis is a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of oral therapies for allergic and dermatologic disease.
Real solutions for diseases that disrupt daily life
We develop therapies that offer real solutions to people affected by allergic and dermatologic conditions — while upholding the highest standards of care and trust in the medical community.
With a focus on delivering safe, effective, and innovative treatments, Calixis aims to improve patients' lives through breakthrough science. We chose to begin with chronic spontaneous urticaria because its biology points clearly to a single, addressable cause: the mast cell.
Principles behind our science
Precision
We pursue targets with clear biological rationale, aiming to treat disease at its source rather than one symptom at a time.
Patients first
Every decision is measured against a simple question: will this meaningfully improve the lives of the people we serve?
Rigor & trust
We hold to the highest standards of scientific and clinical integrity, earning the confidence of physicians, investors, and patients alike.
The moment for mast-cell medicine
Advances in understanding KIT biology and mast-cell disease have opened a path to therapies that were not previously possible.
Calixis was founded to translate that understanding into oral treatments — starting with chronic spontaneous urticaria and extending, over time, to the broader family of mast-cell–driven diseases.
The people behind Calixis
Our team brings together drug discovery, clinical development, and company-building experience.
Eben Tessari
CEO
Kevin Nguyen
SVP, Program Leadership & Operations
Ajay Duggal
CMO
Elizabeth Alexander
VP, Clinical Development
Dan Larson
VP, Development Operations
Maurice Kirby
Director, Development Operations
Backed by blue-chip life-science investors
Calixis is supported by leading venture firms with deep experience building successful biotechnology companies.
Learn more or get involved
Whether you're a physician, potential partner, investor, or patient, we'd love to hear from you.
Contact us